Coal miners lose black lung screenings after Trump slashes NIOSH
"That was the only thing in this area when I graduated high school," Tennant said.
That was in 1974, when Tennant was protected by the National Institute for Occupational Safety and Health, or NIOSH.
For decades it offered free screenings for black lung, a chronic disease caused by prolonged exposure to coal dust. But the screenings have stopped because of President Trump's mandated budget cuts.
Tennant says he's worried for the younger workers.
"What's going to happen, I'm afraid, is your young ones, before they realize what they've done to their body, they're gonna have black lung, and the numbers is going to rise," Tennant said.
Catherine Blackwood was a PhD scientist at the NIOSH facility in Morgantown, West Virginia, where she studied the dangers of mold exposure.
"I'm angry that we are just being cast aside," Blackwood said.
Her job was eliminated April 1, along with over 200 others at the facility — from the people who oversee mine safety to those who study cancer-causing chemicals in firefighters.
"I'm really worried and fearful about what the impacts are going to be on the rest of us," Blackwood said.
And it's not just about Morgantown.
"Every single person faces different hazards at their work every day. And without NIOSH, I think that we are all in danger," Blackwood said.
Although some roles were temporarily reinstated in recent days, the Trump administration still plans to terminate all staff in the coming months, leaving the future of the health screenings and other programs in doubt.
When asked about the cuts to crucial programs, a Health and Human Services spokesperson said in part: "The department remains focused on cutting wasteful bureaucracy and eliminating duplicative administrative roles."
But Blackwood says, "The work being done at NIOSH was not wasteful. It was not duplicative. It was not redundant. The research that was being done at NIOSH was being done nowhere else in the world."
West Virginia isn't only coal country — it's Trump country. He won the state in 2024 with 70% of the vote.
Tennant, now retired, says he didn't vote for former Vice President Kamala Harris or Mr. Trump.
"He's looking at the coal-fired power plants, but he's also doing away with NIOSH that helps the safety of the coal miners," Tennant said.
The budget for NIOSH was about $363 million in 2023, the same year that job injuries and illnesses cost Americans around $176 billion, according to the National Safety Council. Without NIOSH, officials say that number could be higher.
"I don't think it's hyperbole to say that eviscerating NIOSH, as they have, will cause people to die," Blackwood said.
Sneak peek: The Depraved Heart Murder
Why Hegseth is calling for cuts to senior ranks across U.S. military
Reporter's Notebook: Who pays for tariffs?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients with Depression, including Bipolar Depression
This designation expands the addressable population for NRX-100 to the 13 million Americans who consider suicide each year and represents a 10x expansion of the addressable population compared to the Designation granted in 2017 for bipolar depression alone The Designation includes an FDA determination that NRX-100 has the potential to address an unmet need, based on FDA's assessment of the data submitted Determination of "unmet need" is a requirement for a Commissioner's National Priority Voucher (CNPV) program. Suicide is a public health crisis. Approximately 13 million adults seriously consider suicide each year, according to the CDC, 3.7 million make a plan to commit suicide. An American dies from suicide every 11 minutes. Active-duty personnel, veterans, and first responders have a four-fold higher risk of suicide. WILMINGTON, Del., Aug. 11, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced US Food and Drug Administration (FDA) has granted Fast Track designation to NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression. This designation for NRX-100 as a standalone drug is a 10-fold expansion of the addressable population for NRX-100, compared to the designation granted in 2017 for NRX-100 in combination with NRX-101 (DCS/lurasidone) for treatment of Suicidal Bipolar Depression. In granting the Fast Track designation, FDA made the determination that NRX-100 has the potential to address an unmet medical need, based on an assessment of the preliminary data contained in the Fast Track designation request. This determination of unmet medical need aligns with the eligibility requirements for the Commissioner's National Priority Voucher Program (CNPV)i and for the FDA's Accelerated Approval The Company has applied for a CNPV, which has the potential to substantially shorten the review cycle for NRX-100. Several well-controlled trials submitted to FDA in support of Fast Track Designation demonstrated a clinically meaningful and statistically significant reduction of suicidal ideation. In a Columbia University study licensed by NRx, suicidal patients treated with intravenous ketamine demonstrated a 55% response (i.e. 50% reduction in suicidality) compared to a 30% response to active comparator (P<.02).iii In a trial sponsored by the Government of France and licensed by NRx, 63% of patients achieved full remission from suicidal ideation in three days compared to 31% of those who received placebo (P<.001). This effect has not been proven with intranasal administration of "We thank FDA for its thoughtful review of our Fast Track designation request, and believe this regulatory determination is a significant step forward in our goal to address the national crisis of suicide among soldiers, first responders, veterans, and civilians alike." said Dr. Jonathan Javitt, Chairman and CEO of NRx Pharmaceuticals. "Large-scale government-supported trials have demonstrated a robust and statistically significant reduction in suicidal ideation and depression with administration of ketamine. This drug was also proven to be non-inferior to electroshock therapy in treating depression without the negative side effects of ECT. We look forward to working closely with the FDA in our quest to Bring Hope to Life." Under the terms of the Fast Track program, NRx will be posting an expanded access policy for NRX-100 in the next two weeks and seeking a meeting with FDA leadership to finalize the data to be submitted under the Accelerated Approval / CNPV application. In addition to the benefits above, Fast Track Designation also grants enhanced communication with the FDA, as well as potential Priority Review and Rolling Review. NRX-100 in Suicidal Ideation in Patients with Depression, Including Bipolar Depression According to the CDC, approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – is designed to help address this national crisis. NRx will be submitting patient-level data from controlled clinical trials that demonstrate ketamine to be superior to both a placebo and an active comparator, as well as either non-inferior or superior to electroshock therapy in treating various forms of depression, including patients with active suicidal ideation. Although ketamine in various forms is increasingly used to treat depression and related disorders, it is currently only approved by FDA only for use as an anesthetic and, therefore, not reimbursed by most insurance carriers for treatment of suicidality or depression. Intravenous ketamine is reimbursed by the Department of Veterans Affairs and the Department of Defense for its beneficiaries. By applying for FDA labeling for NRX-100 to treat suicidal depression, the Company hopes to make this potentially life-saving therapy available to all Americans, not just those who are able to pay out of pocket. The Company has previously filed full Chemical Manufacturing and Controls (CMC) information for NRX-100 with FDA and has reported stability and sterility data sufficient to anticipate three-year room temperature shelf life for preservative-free ketamine. Having completed this Fast Track Designation, NRx is now filing draft labeling for NRX-100 to comply with the CNPV requirement. NRX-100 is the first preservative-free presentation of ketamine to be filed with FDA. Currently available product, primarily of foreign manufacture, contains a known toxic preservative, Benzethonium Chloride (BZT) that is not Generally Recognized as Safe (GRAS) and is not allowed by FDA to be used in hand cleaners and topical antiseptics. NRx demonstrated long term stability and sterility with its patented preservative-free formulation of NRX-100. The Company has additionally filed a Citizen Petition seeking to have BZT removed from all intravenous ketamine products. The Company has instituted US-based high-volume manufacture of sterile, preservative-free ketamine. Regarding Fast Track designation, FDA's website states: A drug that receives Fast Track designation is eligible for some or all of the following: More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval. More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met. Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA. NRX-100 is poised to address the >$3 billion Suicidal Depression market in the US. References i Grunebaum, et al. Ketamine for rapid reduction of suicidal thoughts… Am J Psychiatry 2018;175: Abbar, et al. Ketamine for the acute treatment of severe suicidal ideation… BMJ 2021;167:194-203 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and the Government of France, licensed under a data sharing agreement. Notice Regarding Forward-Looking StatementsThe information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: Matthew Duffy Chief Business Officer, NRx Pharmaceuticals mduffy@ Brian Korb Managing Partner (917) 653-5122 View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Medical debt can still appear on credit reports, judge rules
A federal judge blocked a rule from the Biden-era Consumer Financial Protection Bureau that would have kept medical debt from appearing on credit reports. Mind Your Money host Julie Hyman reports on the latest. To watch more expert insights and analysis on the latest market action, check out more Mind Your Money. A judge has blocked a Biden era ban on medical debt in credit reports. Now, technically, the rule from the Consumer Financial Protection Bureau never took effect, but if it had, it would have stopped medical bills from appearing on credit reports and barred lenders from using that data to make lending decisions. The CFPB says removing medical bill information could have wiped $49 billion off credit reports of about 15 million Americans and increased their credit scores by an average of 20 points. But a judge ruled in favor of two trade associations that argued the CFPB overstepped its authority in issuing that rule. This comes at a precarious time in health care, with millions of Americans expected to lose health insurance by 2034 due to changes in Medicaid under President Trump's new tax bill. So how does medical debt and your credit report work without this rule? Say you get medical care. The provider will send your bill to insurance, and you're responsible for whatever your insurance does not cover. If you don't pay that balance, the provider will likely send you reminders. If you still don't pay, they may send that debt to a collection agency. Once it's with the agency, they own that debt. They'll start calling and sending you letters, and they may report it to credit bureaus. Once reported, it can appear on your credit report. Now, it may not hurt your credit score right away. Medical debt must be one year old before it shows up on your credit report. Debt under $500 is not reported. And 14 states have provisions in place to remove medical collection debt from credit reports. But still, consumers are left with the responsibility to stay on top of changes to their credit as they face mounting bills.
Atlantic
3 hours ago
- Atlantic
Are You Cowmaxxing?
A not-insignificant number of TikToks aim to convince the viewer that beef-tallow moisturizer will not make your face smell like a cow. The beauty influencers who tend to appear in these videos—usually clear-skinned women rubbing tallow into their face as they detail their previous dermatological woes—describe the scent as 'buttery' or 'earthy' or grass-like. Many of them come to the same conclusion: Okay, even if the tallow does smell a little bit, the smooth skin it leaves behind is well worth it. Beef tallow (as both a moisturizer and an alternative to seed oils) is one of many cow-based products that have crowded the wellness market in the past five or so years. Beef-bone broth is a grocery-store staple. Demand for raw milk has grown, despite numerous cases of illness and warnings from public-health officials that drinking it can be fatal. In certain circles, raw cow organs—heart, liver, kidney—are prized superfoods. Target and Walmart sell supplements containing bovine collagen (a protein found in cowhide and bone) and colostrum (the rich liquid that mammals produce for their newborn offspring); they promise healthier skin, a happier gut, and stronger immunity, and come in flavors such as watermelon lime, lemon sorbet, and 'valiant grape.' You can buy cow-placenta pills for postpartum healing, or powdered bull testicle for testosterone support. The slightest interaction with clean-beauty Instagram can fill your feed with ads for beef-tallow lip balms, cleansing creams, sunscreen, and deodorants. (One brand even offers creamsicle-flavored beef-tallow personal lubricant, which is currently out of stock online.) Influencers praise tallow for clearing their acne and eczema—and offer discount codes so you can experience the same. Even the government's recent public-health messaging has veered toward the bovine. During his tenure as health secretary, Robert F. Kennedy Jr. has championed cooking in beef tallow (which he says is healthier than seed oils) and drinking raw milk (one of many items that he claims are suppressed by the FDA). Casey Means, President Donald Trump's nominee for surgeon general, also supports raw milk; she has suggested that Americans can decide whether a given bottle is safe to drink by looking the dairy farmer in the eye and petting his cow. Means and Kennedy have largely avoided engaging with the many public-health experts who reject their views. But in May, after months of such critiques, Kennedy took shots of raw milk at the White House to celebrate the release of the 'Make America Healthy Again' report. Woo-woo, it seems, is becoming moo-moo. America has entered its cowmaxxing era. Like most wellness offerings, cow products are marketed with vague health claims that are virtually impossible to confirm or deny, such as 'deeply nourishes and supports the skin barrier,' 'activate cellular health,' and 'supports memory.' One of the many promises of the Ancestral Supplements Starter Pack of organ-based capsules is simply 'vitality.' (The company also includes a disclaimer that the FDA has not reviewed said vitality benefits.) Advocates of these goods tend to be more specific in their praise. Raw-milk enthusiasts claim that unpasteurized milk contains bioactive chemicals that improve human health. In one video, a woman drinks raw milk that's been in the fridge for more than a month; she claims it is safer to consume than store-bought pizza or salad and that it reduces rates of eczema, fevers, and respiratory infections. One smooth-skinned influencer, who says she hasn't washed her face in two years, claims that beef tallow is 'bioidentical' to the sebum produced by human skin. (It's not, because it's from cows.) Some of these products are more likely to provide benefits than others. Bone broth is indeed rich in collagen (which, when produced by the human body, strengthens hair and skin). Whey powder, made from leftover cheese water, does contain protein. But very few studies support the idea that eating more collagen strengthens hair and skin. Whey protein can help build lean muscle, but the body can only absorb so much at a time. Some dermatologists say tallow can strengthen and hydrate the skin; others say it clogs pores and should be avoided. Other products can be downright dangerous: Just this week, Florida officials announced that 21 people fell sick after consuming contaminated raw milk. At least part of the appeal of cowmaxxing is the cows themselves: The products evoke the pastoral ideal of a cow grazing freely in the plains, milked lovingly by human hands. It's an image that's been embedded in American culture for centuries. Consider how Laura Ingalls Wilder, who was no stranger to the harsh reality of farm life, described cow-raising in Little Town on the Prairie: 'Warm and sweet, the scent of new milk came up from the streams hissing into the rising foam, and it mixed with the scents of springtime.' It's enough to persuade a microbiologist to drink raw milk. In 21st-century America, cows still summon images of fields and clover and wide blue sky, enough to trigger the human tendency to believe that what's natural is 'fundamentally good,' Courtney Lappas, a biology professor at Lebanon Valley College, told me. Her research has shown that some Americans prefer natural over man-made products even when the former is described as objectively worse—a phenomenon her colleague Brian Meier has called the 'naturalness bias.' This tendency, which is prevalent across cultures, likely leads people to assume that unprocessed cow-based products are safe and healthy, she said. Tallow, some skin-care enthusiasts claim, is a healthier, safer alternative to conventional moisturizers, which supposedly contain toxic chemicals. The branding of such products, too, leans into the notion that natural is best: Fat Cow Skincare markets its tallow cosmetics as 'pure skincare, powered by nature'; Heart and Soil sells capsules of 'nature's superfood' (that is, organ meats). Other brands invoke nature through the prehistoric, with names such as Primal Harvest, Primal Kitchen, Primal FX, Primal Being, and Primal Queen. Ancestral Supplements' ad copy reads: 'Putting Back In What the Modern World Left Out.' America's current health landscape is the perfect setting for cowmaxxing to thrive. The naturalness bias is deeply ingrained in Kennedy's MAHA campaign, which aims to improve public health by returning to a more natural lifestyle. In Kennedy's view, beef tallow is superior to seed oil because it's less processed (some people even render it at home). The carnivore and tradwife movements embody a similar message, promoting the consumption of raw cow organs and making butter from scratch. You may not know what's in store-bought products, the thinking goes, but you do know what's in tallow: pure, unadulterated cow fat. And yet most modern cows live in a decidedly unnatural environment. The majority of U.S. cattle are fed genetically modified crops, and some genetically modified cows are allowed to be sold as food. Many cow-based wellness products bear the label 'grass-fed,' which suggests cows that were raised on pastures rather than feedlots. But the label is not strictly enforced, and it doesn't necessarily prohibit farmers from giving cows antibiotics or hormones. There's no guarantee that a cow whose colostrum is harvested to be sold by a tradwife on Instagram had a happy, bucolic existence. Not to mention that colostrum, whey, and placenta do not come out of the cow in the form of powders or pills. The spread of science misinformation, along with legitimate concerns about the state of public health in the United States, have left many Americans understandably confused about whether conventional science and Western medicine can be trusted in 2025. Getting to the bottom of, say, the seed-oil controversy requires engaging with thorny scientific debates that reference inscrutable research papers; embracing the natural and ancestral by opting for tallow is an attractively simple-seeming alternative. 'It brings with it a sense of purity or wholesomeness that is desirable right now,' Marianne Clark, a sociologist at Acadia University who studies wellness trends, told me. In this sense, cowmaxxing is not so much a health endeavor as it is a spiritual one, its promise downright biblical: Cowliness is next to godliness.
